CASIF
CASI Pharmaceuticals, Inc.
$0.1800
+28.57%
No data for this timeframe.
Vol
SEC Reports6
Recent Activity
Jun 2, 2026
SEC
CASI Pharmaceuticals disclosed the resignation of director Dr. Barbara Krebs-Pohl, effective May 31, 2026, with no disag
6-K — Impact 2/10
Apr 23, 2026
SEC
Thomas Folinsbee, an officer of CASI Pharmaceuticals, filed a Form 3 disclosing ownership of stock options. The filing i
3 — Impact 2/10
Apr 20, 2026
SEC
CASI Pharmaceuticals announced the departure of its Global Chief Medical Officer, Dr. Alexander A. Zukiwski, effective A
6-K — Impact 3/10
Price Targets
Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$4.00 (Sep 2025)
Current $0.1800
Low $4.00
Median $4.00
High $4.00
1 analysts
$4.00
$4.00
Analyst Ratings
3Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 3, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.36 ▲ +2.7% | $-0.36 — $-0.36 | 48% YoY | 1 |
| Next Q | $-0.35 ▲ +2.8% | $-0.35 — $-0.35 | 59% YoY | 1 |
| Current FY | $-1.41 ▲ +2.8% | $-1.41 — $-1.41 | 46% YoY | 1 |
| Next FY | $-1.39 ▲ +1.4% | $-1.39 — $-1.39 | 1% YoY | 1 |
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 5 neutral. Avg impact: 3.2/10.
NEUTRAL
6-K
2/10
CASI Pharmaceuticals disclosed the resignation of director Dr. Barbara Krebs-Pohl, effective May 31,
Jun 2, 2026
NEUTRAL
3
2/10
Thomas Folinsbee, an officer of CASI Pharmaceuticals, filed a Form 3 disclosing ownership of stock o
Apr 23, 2026
NEUTRAL
6-K
3/10
CASI Pharmaceuticals announced the departure of its Global Chief Medical Officer, Dr. Alexander A. Z
Apr 20, 2026
BEARISH
6-K
6/10
CASI Pharmaceuticals announced the closing of the fourth and final tranche of its $20 million conver
Apr 20, 2026
NEUTRAL
6-K
3/10
CASI Pharmaceuticals announced that its ordinary shares began trading on the OTCQB under the ticker
Apr 15, 2026
NEUTRAL
3
3/10
Alexander Zukiwski, Global Chief Medical Officer of CASI Pharmaceuticals, filed a Form 3 disclosing
Apr 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Sep 2025): 89% buy across 9 analysts — 3 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$4.00 mean target (Sep 2025)
$4.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $0.1800 |
| Target Low | $4.00 |
| Target Mean | $4.00 |
| Target Median | $4.00 |
| Target High | $4.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-0.36 | $-0.36 | $-0.36 | 47.8% | +2.7% | — | $0.0B | -100.0% | 1 |
| Next Q 2026-06-30 |
$-0.35 | $-0.35 | $-0.35 | 59.3% | +2.8% | — | $0.0B | -100.0% | 1 |
| Current FY 2026-12-31 |
$-1.41 | $-1.41 | $-1.41 | 45.6% | +2.8% | 1↑ 0↓ | $0.0B | -100.0% | 1 |
| Next FY 2027-12-31 |
$-1.39 | $-1.39 | $-1.39 | 1.4% | +1.4% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.360 | |
| 7d ago | $-0.370 | +0.010 |
| 30d ago | $-0.370 | +0.010 |
| 60d ago | $-0.370 | +0.010 |
| 90d ago | $-0.370 | +0.010 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Sep 3, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.